Benzodiazepine Use and Dependence in Relation to Chronic Pain Intensity and Pain Catastrophizing
Overview
Affiliations
Benzodiazepines (BZDs), a class of sedative-hypnotic medications, generated concern as their popularity grew, with particular alarm regarding elevated rates of BZD use among chronic pain populations. Consistent with negative reinforcement/motivational models of substance use, desire for pain alleviation may motivate BZD use. Yet, little is known about relations between pain and addiction-relevant BZD use processes. This cross-sectional survey study aimed to: a) test associations between pain intensity and clinically relevant BZD use patterns, and b) examine the role of pain catastrophizing in hypothesized pain-BZD relations. Participants included 306 adults with chronic musculoskeletal pain and a current BZD prescription who completed an online survey study (M = 38.7, 38.9% female). Results indicated that pain intensity was positively associated with past-month BZD use frequency, BZD dependence severity, and likelihood of endorsing BZD misuse behaviors (ps < .05). Pain catastrophizing was positively associated with BZD dependence/likelihood of BZD misuse, covarying for pain intensity (P < .05). These findings build upon an emerging literature by highlighting positive covariation of pain intensity and pain catastrophizing with addiction-relevant BZD use behaviors. Results underscore the need to further investigate high-risk BZD use among individuals with chronic pain, with and without concurrent opioid use, to inform prevention/intervention efforts. PERSPECTIVE: This article presents findings on cross-sectional associations of pain intensity and pain catastrophizing with clinically relevant benzodiazepine (BZD) use outcomes, including dependence and misuse, among individuals with chronic pain. Findings help elucidate the higher burden of BZD misuse/dependence in chronic pain populations and suggest that pain relief may be a common, yet under recognized, self-reported motivation for taking BZDs.
Zamani K, Fakhri S, Kiani A, Abbaszadeh F, Farzaei M Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39912904 DOI: 10.1007/s00210-025-03842-4.
Hashemi B, Fakhri S, Kiani A, Abbaszadeh F, Miraghaee S, Mohammadi M Front Pharmacol. 2024; 15:1467788.
PMID: 39654618 PMC: 11625551. DOI: 10.3389/fphar.2024.1467788.
Baron R, Morlion B, Dahan A, Uberall M, von Basum G, Wild I Front Pain Res (Lausanne). 2024; 5:1444401.
PMID: 39109241 PMC: 11300367. DOI: 10.3389/fpain.2024.1444401.
Initial validation of the expectancies for Benzodiazepine Analgesia Scale.
Lape E, Powers J, LaRowe L, Ditre J Exp Clin Psychopharmacol. 2023; 32(3):369-378.
PMID: 38010761 PMC: 11098706. DOI: 10.1037/pha0000692.